Cardiogen
/ Khavinson-tradition tripeptide (Ala-Glu-Asp); proposed cardiac muscle bioregulatorALIAS · AED · Ala-Glu-Asp · Cardiac peptide bioregulator
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. No PubMed-indexed primary study isolates cardiogen as the studied agent; the tripeptide AED appears as one of several peptides in broader Khavinson-group cell-culture and gene-expression panels rather than as the focus of dedicated work. No Western Phase 1 or later trials.
Cardiogen is a synthetic tripeptide of the Khavinson sequence-specific bioregulator class proposed to act on cardiac muscle tissue. The class-level hypothesis is that short peptides bind DNA and influence transcription of tissue-relevant genes, with sequence selectivity assigning the target tissue. For cardiogen, no peptide-specific mechanistic dataset is available in indexed primary literature; the AED tripeptide appears as one of several test peptides in broader Khavinson-group panels (e.g. proliferation and apoptosis assays in fibroblast cultures).
Tier 4. No peptide-specific primary clinical or preclinical study identifies cardiogen as the studied agent in indexed PubMed literature. There is no replicated independent evidence base for this compound.
No formal human safety database. No peptide-specific safety record beyond inclusion in broader Khavinson-group cell-culture panels.
Regulatory status
- FDA status:
- Not FDA-approved
Russian-origin literature (Khavinson group, Saint-Petersburg Institute of Bioregulation and Gerontology) without independent Western replication, with the additional issue that cardiogen specifically has no replicated independent evidence base — even within the Khavinson corpus, the AED tripeptide appears alongside KE, KED, and AEDG rather than as a distinctly studied compound. Vendor sales presume cardiac-specific bioactivity that the published record does not establish.